Charles Marcus
Overview
Explore the profile of Charles Marcus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
685
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lawal I, Gbolahan O, Marcus C, Jones A, Shaib W, Muzahir S
Clin Nucl Med
. 2025 Mar;
PMID: 40029803
A 56-year-old woman with sickle cell anemia (SCA) and metastatic neuroendocrine tumor refractory to somatostatin analog received 4 cycles of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE. The treatment schedule...
2.
Lawal I, Mushtaq A, Jani A, Rupji M, Dhere V, Patel S, et al.
J Nucl Med
. 2025 Jan;
66(2):230-237.
PMID: 39848765
Radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) have emerged as a sensitive tool for PET imaging of prostate cancer (PCa) recurrence. Yet urinary bladder activity may obscure the visualization of prostate...
3.
Marcus C, Muzahir S, Subramaniam R
PET Clin
. 2023 Dec;
19(2):187-196.
PMID: 38160070
Significant improvement in molecular imaging and theranostics in the management of neuroendocrine tumors (NETs) has been made in the last few decades. Somatostatin receptor-targeted PET imaging outperforms conventional, planar, and...
4.
5.
Arntz P, Deroose C, Marcus C, Sturesson C, Panaro F, Erdmann J, et al.
HPB (Oxford)
. 2023 Jul;
25(10):1131-1144.
PMID: 37394397
Purpose: The aim of this joint EANM/SNMMI/IHPBA procedure guideline is to provide general information and specific recommendations and considerations on the use of [Tc]Tc-mebrofenin hepatobiliary scintigraphy (HBS) in the quantitative...
6.
Ali A, Sivathapandi T, Gupta R, Master V, Marcus C
Clin Nucl Med
. 2023 Jun;
48(8):e390-e392.
PMID: 37335313
Preoperative differentiation of oncocytomas from renal cell carcinoma (RCC) is often challenging. 99m Tc-MIBI imaging could play a potential role in differentiating oncocytoma from RCC, which in turn could guide...
7.
Lawal I, Marcus C, Schuster D, Goyal S, Adediran O, Dhere V, et al.
Clin Nucl Med
. 2023 Feb;
48(4):e153-e159.
PMID: 36754362
Purpose: We aimed to evaluate the impact of 18 F-fluciclovine PET/CT imaging on failure-free survival (FFS) post-salvage radiotherapy (SRT) for prostate cancer (PCa) recurrence. Methods: Seventy-nine patients were recruited in...
8.
Wu C, Marcus C, Baum Y, Kucuk O, Schuster D
Clin Nucl Med
. 2023 Feb;
48(4):361-363.
PMID: 36728146
18 F-fluciclovine (Axumin; Blue Earth Diagnostics, Ltd, Oxford, United Kingdom) PET has shown value in detecting biochemical recurrent prostatic cancer. Lycopene, a plant-based carotenoid, is reported to have potential inhibitory...
9.
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
Fendler W, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al.
Eur J Nucl Med Mol Imaging
. 2023 Jan;
50(5):1466-1486.
PMID: 36604326
Here we aim to provide updated guidance and standards for the indication, acquisition, and interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics are reported for a variety...
10.
Marcus C, Subramaniam R
PET Clin
. 2022 Dec;
18(2):233-242.
PMID: 36585340
Molecular imaging evaluation of pheochromocytomas and paragangliomas depends on multiple factors, such as localized versus metastatic disease, the genetic, and biochemical profile of tumors. Positron emission tomography/computed tomography (PET/CT) imaging...